|Videos|June 15, 2022
A US-Based, Injectables-Focused CDMO with Available Capacity and End-to-End Capabilities
Author(s)August Bioservices
Ryan Downey, Director of Customer Operations, outlines August Bioservices’ capabilities for its customers and what it means to work with them.
- They focus on sterile injectables in multiple container sizes from vials to syringes to flexible IV bags— coupled with an analytical services department.
- The current CDMO market is constrained for those who need the capacity to start their innovative work, which is where August Bioservices comes in.
- With robust tools and a strong team, they can solve difficult challenges with formulation, commercial configuration, the timing of a project, and analytical characterizations.
Related Content
Trending on Pharmaceutical Technology
1
The FDA Moves to Modernize Drug Manufacturing Registration
2
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
3
PharmTech Weekly Roundup–July 10, 2026
4
Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies
5